Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma.

@article{Iwamoto2009PatternsOR,
  title={Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma.},
  author={Fabio M. Iwamoto and Lauren E. Abrey and Kathryn Beal and P H Gutin and Marc K. Rosenblum and Vicor E Reuter and Lisa M DeAngelis and Andrew B. Lassman},
  journal={Neurology},
  year={2009},
  volume={73 15},
  pages={
          1200-6
        }
}
BACKGROUND Bevacizumab has recently been approved by the US Food and Drug Administration for recurrent glioblastoma (GBM). However, patterns of relapse, prognosis, and outcome of further therapy after bevacizumab failure have not been studied systematically. METHODS We identified patients at Memorial Sloan-Kettering Cancer Center with recurrent GBM who discontinued bevacizumab because of progressive disease. RESULTS There were 37 patients (26 men with a median age of 54 years). The most… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 193 CITATIONS, ESTIMATED 50% COVERAGE

Role of bevacizumab therapy in the management of glioblastoma

  • Cancer management and research
  • 2010
VIEW 3 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

Survival of patients with newly diagnosed glioblastoma treated with radiation and temozolomide in research studies in the United States.

  • Clinical cancer research : an official journal of the American Association for Cancer Research
  • 2010
VIEW 4 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

FILTER CITATIONS BY YEAR

2009
2019

CITATION STATISTICS

  • 7 Highly Influenced Citations

  • Averaged 12 Citations per year from 2017 through 2019